Invests in
Locations:
Min Investment:
$500,000.00Max Investment:
$15,000,000.00Target Investment:
$7,000,000.00
Skills
Education
Lists including Sabrina
Work Experience
2017
Senior Principal
2017
Leading Flagship-founded bio platform companies from seed through Series B. Co-founded Empress Therapeutics and FL91 (now Ampersand Biomedicines) Leading entrepreneurial scientists in developing category-defining life sciences NewCo’s by exploring hundreds of venture ideas, conducting KOL calls, presenting company creation and investment plan to investment committee. Responsible for NewCo R&D strategy, business development, IP strategy, team formation, company milestones, platform proof points, developing budget, and interfacing with board members, scientific advisors, and consultants.
2018
Chief Innovation Officer
2022
Leading platform innovation, corporate partnership, and external research collaboration
Co-Founder
2018
2021 - 2023
Co-Founder
2021 - 2023
FL91 is a Flagship founded platform company with the mission to make biologic drugs safer, based on a novel category of proteins that activate homeostasis-promoting pathways only at the disease site.
2016 - 2017
Translational Fellow
2016 - 2017
NSF Innovation Corps Translational Fellow: from research idea to commercialization. - Developed a small molecule T-cell targeting drug delivery platform for cancer immunotherapy - Project leader in the Biomed Entrepreneurship Course at the Broad Institute - Podium speaker at 2017 Immunotherapy of Cancer Conference (ITOC4) in Prague, Czech Republic - Selected participant in Harvard Healthcare Innovation and Commercialization semester-long course: start-ups, intellectual properties, venture capital, market analysis, investments, and pitch to VCs.
2017 - 2017
Venture Creation Fellow
2017 - 2017
Originate first-in-category platform technology ideas through effective analytical, communication and teamwork skills. Pitch company idea and plans to Flagship partners and CEO.
2011 - 2016
Doctoral Researcher
2011 - 2016
Laboratory of Dr. Darrell Irvine (HHMI investigator) at the Koch Institute of Integrative Cancer Research - Developed a strategy to enhance intracellular small molecule drug targeting to CD8+ T cells in vivo. Filed two patents. - Collaborated with computational scientists to understand the mechanisms of cell membrane penetration and fusion dynamics. - Podium Speaker at 2016 Keystone Symposium: Antibodies as Drugs and Cancer Vaccines, Whistler, Canada. - Poster presentation at 2015 Gordon Research Conference: Cancer Nanotechnology, Vermont. - Podium Speaker at 2014 BMES, San Antonio, Texas. - Silver Awards in MIT Materials Prototyping Contest (2013): Designed and built a solar-powered LED embedded in flexible material that lights up off-grid places.
2014 - 2014
Visiting Scholar
2014 - 2014
2009 - 2009
Researcher
2009 - 2009
Iron platinum nano alloy synthesis, characterization and applications in MRI/CT molecular contrast agents.